Alzheimer's disease therapeutic candidate SAK3 is an enhancer of T-type calcium channels

Citations of this article
Mendeley users who have this article in their library.


Low-threshold Ca 2+ spikes are mediated by T-type Ca 2+ channels, which have electrophysiological properties of fast inactivation and slow deactivation kinetics. A low membrane potential of approximately −60 mV is sufficient to trigger channel opening. We recently introduced a novel T-type Ca 2+ channel enhancer that improves cognition and inhibits amyloid beta aggregation in an Alzheimer's disease (AD) mouse model. The enhancer stimulates ACh release, Ca 2+ /calmodulin-dependent protein kinase II (CaMKII) activity, and neurogenesis in the hippocampus. Then, we discuss how T-type Ca 2+ channel enhancer improves cognition and impaired neurogenesis and how CaMKII signaling in neurodegenerative diseases reduces amyloid beta aggregation. We provide a perspective of the potential AD therapies to target CaMKII signaling. In this context, we overview our attempts leading to the development of a T-type Ca 2+ channel enhancer as cognitive enhancer, the action of which has been associated with CaMKII and presumably proteasome activity.




Fukunaga, K., Izumi, H., Yabuki, Y., Shinoda, Y., Shioda, N., & Han, F. (2019, February 1). Alzheimer’s disease therapeutic candidate SAK3 is an enhancer of T-type calcium channels. Journal of Pharmacological Sciences. Japanese Pharmacological Society.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free